中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

286 records (took 0.022 seconds)

    GAMMARETROVIRUS ASSOCIATED WITH CANCER
    213.
    发明申请
    GAMMARETROVIRUS ASSOCIATED WITH CANCER 审中-公开
    与癌症相关的巨噬细胞瘤

    公开(公告)号：WO2006110589A2

    公开(公告)日：2006-10-19

    申请号：PCT/US2006013167

    申请日：2006-04-07

    Applicant: CLEVELAND CLINIC FOUNDATION ,  UNIV CALIFORNIA ,  SILVERMAN ROBERT ,  KLEIN ERIC A ,  DERISI JOSEPH ,  GANEM DON ,  CASEY GRAHAM

    Inventor： SILVERMAN ROBERT ,  KLEIN ERIC A ,  DERISI JOSEPH ,  GANEM DON ,  CASEY GRAHAM

    CPC classification number: C12N7/00 ,  A61K39/00 ,  C07K14/005 ,  C07K16/1036 ,  C12N9/22 ,  C12N2740/13021 ,  C12N2740/13022 ,  C12Q1/6886 ,  C12Q1/70 ,  C12Q1/701 ,  C12Q2600/136

    Abstract: The present invention provides for isolated nucleic acid sequences encoding viruses; isolated polypeptides comprising amino acid sequences of the virus; vectors comprising the viral nucleic acid sequences; cells comprising the vectors; antibodies and antigen binding fragments thereof which have binding specificity for the virus; methods of detecting or screening for the virus (e.g., in an individual); methods of identifying agents that inhibit the virus; methods of inducing an immune response to the virus; methods of treating disease associated with the presence of XMRV in an individual (e.g., cancer such as prostate cancer); methods of detecting asymptomatic cancer (e.g., prostate cancer); methods of identifying an individual at risk for developing cancer (e.g., prostate cancer); and kits for detecting the virus.

    Abstract translation: 本发明提供了编码病毒的分离的核酸序列; 包含病毒的氨基酸序列的分离的多肽; 包含病毒核酸序列的载体; 包含载体的细胞; 对病毒具有结合特异性的抗体及其抗原结合片段; 检测或筛选病毒的方法（例如，在个体中）; 识别抑制病毒的药剂的方法; 诱导对病毒的免疫应答的方法; 治疗与个体（例如癌症如前列腺癌）中XMRV存在相关的疾病的方法; 检测无症状癌症的方法（例如前列腺癌）; 识别患有癌症风险的个体（例如前列腺癌）的方法; 和用于检测病毒的工具包。

    PEPTIDES DERIVED FROM THE SUPERANTIGEN (SAG) ENV PROTEIN OF HERV-K18 AND THEIR USE IN OBTAINING SAG-INHIBITORY ANTIBODIES AND IN VACCINATION AGAINST SAG
    214.
    发明申请
    PEPTIDES DERIVED FROM THE SUPERANTIGEN (SAG) ENV PROTEIN OF HERV-K18 AND THEIR USE IN OBTAINING SAG-INHIBITORY ANTIBODIES AND IN VACCINATION AGAINST SAG 审中-公开
    衍生自HERV-K18的超抗原（SAG）ENV蛋白的肽以及它们在获得SAG-抑制性抗体和对抗SAG的疫苗中的用途

    公开(公告)号：WO2003022867A2

    公开(公告)日：2003-03-20

    申请号：PCT/EP2002/011049

    申请日：2002-09-06

    Applicant: NOVIMMUNE S.A. ,  DUPUIS, Marc

    Inventor： DUPUIS, Marc

    IPC: C07K

    CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/575 ,  A61K2039/6081 ,  C07K16/1036 ,  C12N2740/10022 ,  C12N2740/10034

    Abstract: The present invention relates to peptides derived from the superantigen (Sag) ENV protein of the human endogenous retrovirus HERV-K18, and to the use of the peptides in obtaining antibodies which inhibit the superantigen activity of HERV-K18 ENV. The invention also relates to vaccine compositions for treating and preventing disorders associated with the ENV gene product of HERV-K18, for example autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM). A preferred peptide consists of a portion of an N- or C-terminal segment of the HERV-K18.1 ENV protein, as illustrated in Figure 1A, said N-terminal segment extending from amino acids 22 to 62 of HERV-K18.1 ENV, and said C-terminal segment extending from amino acids 110 to 153 of HERV-K18.1 ENV, wherein the peptide has a length of 6 to 40 amino acids and is capable of giving rise to antibodies which inhibit superantigen activity associated with HERV-K18 envelope proteins.

    Abstract translation: 本发明涉及源自人内源性逆转录病毒HERV-K18的超抗原（Sag）ENV蛋白的肽，并且涉及该肽在获得抑制HERV-K18的超抗原活性的抗体中的用途， K18 ENV。 本发明还涉及用于治疗和预防与HERV-K18的ENV基因产物有关的病症的疫苗组合物，例如自身免疫疾病如胰岛素依赖性糖尿病（IDDM）。 如图1A所示，优选的肽由HERV-K18.1Ev蛋白的N-或C-末端片段的一部分组成，所述N-末端片段从HERV-K18.1的氨基酸22至62延伸 ENV，并且所述C端片段从HERV-K18.1 ENV的氨基酸110至153延伸，其中所述肽具有6至40个氨基酸的长度并且能够产生抑制与HERV相关的超抗原活性的抗体 -K18包膜蛋白。

    PAPUA NEW GUINEA HUMAN T-LYMPHOTROPIC VIRUS
    215.
    发明申请
    PAPUA NEW GUINEA HUMAN T-LYMPHOTROPIC VIRUS 审中-公开
    PAPUA新几内亚人类T淋巴细菌病毒

    公开(公告)号：WO1993003759A1

    公开(公告)日：1993-03-04

    申请号：PCT/US1992006468

    申请日：1992-08-12

    Applicant: THE UNITED STATES OF AMERICA, represented by THE ...

    Inventor： THE UNITED STATES OF AMERICA, represented by THE ... ,  YANAGIHARA, Richard ,  NERURKAR, Vivek, R. ,  JENKINS, Carol ,  MILLER, Mark, A. ,  GARRUTO, Ralph, M.

    IPC: A61K39/00

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K16/1036 ,  C12N7/00 ,  C12N2510/00 ,  C12N2740/14021 ,  C12N2740/14022

    Abstract: The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian populations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.

    Abstract translation: 本发明涉及持续感染巴布亚新几内亚（PNG）HTLV-1变体和感染病毒（PNG-1变体）的人T细胞系（PNG-1）。 本发明的细胞表达病毒抗原，C型粒子并具有低水平的逆转录酶活性。 这种细胞系的建立是来自巴布亚新几内亚的第一种细胞系，使得可以使用当地病毒株筛选美拉尼西亚人群。 本发明还涉及用于人类针对感染的疫苗和由HTLV-1和相关病毒引起的疾病。 本发明还涉及用于检测和诊断由HTLV-1和相关病毒引起的感染和疾病的各种生物测定和试剂盒。

    PAPUA NEW GUINEA HUMAN T-LYMPHOTROPIC VIRUS
    216.
    发明申请
    PAPUA NEW GUINEA HUMAN T-LYMPHOTROPIC VIRUS 审中-公开
    PAPUA新几内亚人类T淋巴细菌病毒

    公开(公告)号：WO1992003160A1

    公开(公告)日：1992-03-05

    申请号：PCT/US1991005896

    申请日：1991-08-23

    Applicant: THE UNITED STATES OF AMERICA, as represented by ... ,  YANAGIHARA, Richard ,  GARRUTO, Ralph ,  MILLER, Marc ,  NERURKAR, Vivek

    Inventor： THE UNITED STATES OF AMERICA, as represented by ...

    IPC: A61K39/12

    CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K16/1036 ,  C12N7/00 ,  C12N2740/14021 ,  C12N2740/14022

    Abstract: The present invention relates to a human T-cell line (PNG-1) persistently infected with a Papua New Guinea (PNG) HTLV-I variant and to the infecting virus (PNG-1 variant). Cells of the present invention express viral antigens, type C particles and have a low level of reverse transcriptase activity. The establishment of this cell line, the first of its kind from an individual from Papua New Guinea, makes possible the screening of Melanesian polulations using a local virus strain. The present invention also relates to vaccines for use in humans against infection with and diseases caused by HTLV-I and related viruses. The invention further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-I and related viruses.

    Abstract translation: 本发明涉及持续感染巴布亚新几内亚（PNG）HTLV-1变体和感染病毒（PNG-1变体）的人T细胞系（PNG-1）。 本发明的细胞表达病毒抗原，C型粒子并具有低水平的逆转录酶活性。 这种细胞系的建立是来自巴布亚新几内亚的第一种细胞系，使得可以使用当地病毒株筛选美拉尼西亚的细菌。 本发明还涉及用于人类针对感染的疫苗和由HTLV-1和相关病毒引起的疾病。 本发明还涉及用于检测和诊断由HTLV-1和相关病毒引起的感染和疾病的各种生物测定和试剂盒。

Patent Agency Ranking